Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 40.4258
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 963348484992.0
- FreeCF/Share 10.0576
- PFCF 106.7931
- PE 52.2408
- Debt/Assets 0.3698
- DivYield 0.0056
- ROE 1.0226
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
News
Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition
Published: December 01, 2025 by: Proactive Investors
Sentiment: Neutral
Eli Lilly and Co (NYSE:LLY) said on Monday it is lowering the cash prices of its weight-loss drug Zepbound, marking the latest move in a growing price battle with rival Novo Nordisk. The US pharmaceutical giant said single-dose vials of Zepbound will now be available on its direct-to-consumer platform, LillyDirect, at reduced prices.
Read More
Eli Lilly Stock in Focus After Slashing Cost of Popular Drug
Published: December 01, 2025 by: Schaeffers Research
Sentiment: Negative
Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound.
Read More
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal
Published: December 01, 2025 by: Forbes
Sentiment: Positive
$1,086. That's the monthly cost of Zepbound before any discounts or rebates, according to Eli Lilly. The list price for Ozempic is just over $997 per month.
Read More
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
Published: November 28, 2025 by: Investopedia
Sentiment: Positive
A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
Read More
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Published: November 24, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Read More
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Published: November 24, 2025 by: PRNewsWire
Sentiment: Neutral
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve CLL/SLL patients – will be presented as an oral presentation Results from the Phase 3 BRUIN CLL-313 study of pirtobrutinib in patients with treatment-naïve CLL/SLL will be featured as a late-breaking oral presentation Both BRUIN CLL-314 and BRUIN CLL-313 were selected to be part of the official ASH press program INDIANAPOLIS , Nov. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the …
Read More
Eli Lilly Stock Joins $1 Trillion Club: What Is Happening?
Published: November 24, 2025 by: Forbes
Sentiment: Positive
Eli Lilly's stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement surrounding revolutionary GLP-1 and oral drug potentials. Let's explore the factors behind this extraordinary surge.
Read More
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
Read More
Eli Lilly becomes first health-care company to hit $1 trillion
Published: November 21, 2025 by: Fast Company
Sentiment: Positive
Silicon Valley's giants crowd the list of the world's most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of one trillion dollars on Friday, becoming the first business in the health industry to hit that milestone.
Read More
3 Weight-Loss Drug Stocks To Consider For 2026
Published: November 21, 2025 by: Benzinga
Sentiment: Positive
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.
Read More
Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
Published: November 21, 2025 by: Reuters
Sentiment: Positive
Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Read More
Eli Lilly's Market Cap Breaks $1 Trillion After Climbing $400 Billion in 3 Months
Published: November 21, 2025 by: Barrons
Sentiment: Positive
It's the only drug company ever to have a $1 trillion capitalization value; the other U.S. companies are tech giants and Berkshire Hathaway.
Read More
Eli Lilly first healthcare company to hit $1T market capitalization
Published: November 21, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) briefly reached a market capitalization of $1 trillion during trading on Friday, making it the first healthcare company to achieve this milestone. Shares of the Indianapolis-based drugmaker rose as much as 1.7% just shy of $1,060, bringing its market value to roughly $1 trillion before retreating slightly, with stock trading near $1,050 per share later in the session.
Read More
Zepbound maker Eli Lilly hits $1T market cap — becoming first drug company to reach milestone
Published: November 21, 2025 by: New York Post
Sentiment: Positive
A more than 35% rally in the company's stock this year has largely been driven by the explosive growth of the weight-loss drug market.
Read More
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
Published: November 21, 2025 by: Investopedia
Sentiment: Neutral
November's Wall Street obsession hasn't been AI. It's been healthcare.
Read More
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.
Published: November 21, 2025 by: Market Watch
Sentiment: Positive
Eli Lilly briefly crossed the $1 trillion market cap threshold, the first drug maker to ever reach that milestone.
Read More
Eli Lilly hits $1 trillion market value, a first for a health-care company
Published: November 21, 2025 by: CNBC
Sentiment: Positive
Drugmaker Eli Lilly reached a $1 trillion market capitalization, the first health-care company in the world to join the exclusive club dominated by tech firms. The pharmaceutical giant's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
Read More
ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:
Published: November 21, 2025 by: WSJ
Sentiment: Positive
Plus, new hormone therapy guidelines, breast-cancer pills and obesity drug price cuts, in this edition of the WSJ Health newsletter.
Read More
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
Published: November 21, 2025 by: Reuters
Sentiment: Positive
Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales channels.
Read More
Ilant Health Enhances Comprehensive Cardiometabolic Care with Direct Contracting for Obesity Management Medicine for Employers
Published: November 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $LLY #GLP1--Ilant Health announced that it will offer employers direct contracting and transparent pricing of Eli Lilly and Company (Lilly) obesity management medicines. Employers working with Ilant Health will have the option of accessing obesity management medicines at a transparent and predictable price point starting in early 2026. Medications obtained through this collaboration will be fulfilled by a licensed mail-order pharmacy, supporting convenience, continuity, and a sea.
Read More
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Baron Opportunity Fund Q3 2025 Portfolio Update
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises. We initiated a starter position in Synopsys after shares sold off following the company's third quarter earnings report and our in-person meeting with management. We exited our CyberArk Software Ltd. position after its acquisition by Palo Alto Networks was announced.
Read More
Lilly to participate in Citi's 2025 Global Healthcare Conference
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Nov. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m.
Read More
Eli Lilly Stock To $1,330?
Published: November 18, 2025 by: Forbes
Sentiment: Positive
Eli Lilly's stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally is fueled by several powerful factors, including robust sales of its weight-loss drug Zepbound and diabetes drug Mounjaro, strong third-quarter financial results, and a recent government agreement regarding Medicare drug price negotiation.
Read More
Alger Growth & Income Fund Q3 2025 Portfolio Update
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Class A shares of the Alger Growth & Income Fund outperformed the S&P 500 Index during the third quarter of 2025. Apple Inc., Broadcom Inc., and Alphabet Inc. were among the top contributors to performance. Honeywell International Inc., Eli Lilly and Company, and TransDigm Group Incorporated were among the top detractors from performance.
Read More
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.
Published: November 17, 2025 by: Barrons
Sentiment: Negative
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Read More
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000